BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brandi G, De Lorenzo S, Di Girolamo S, Bellentani S, Saccoccio G, Biasco G. Fulminant Hepatitis in a Patient with Hepatocellular Carcinoma Related to Nonalcoholic Steatohepatitis Treated with Sorafenib. Tumori 2015;101:e46-8. [DOI: 10.5301/tj.5000247] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Florita A, Morittu E, Galeone C, Leon AE, Ballarini R, Zuanetti G. Variables affecting evaluation and publication of oncology case reports: a systematic analysis. Int J Biol Markers 2016;31:e456-60. [PMID: 27834462 DOI: 10.5301/jbm.5000237] [Reference Citation Analysis]
2 Goody RB, Brade AM, Wang L, Craig T, Brierley J, Dinniwell R, Wong RKS, Cho C, Kim J, Kassam Z, Ringash J, Knox JJ, Dawson LA. Phase I trial of radiation therapy and sorafenib in unresectable liver metastases. Radiother Oncol 2017;123:234-9. [PMID: 28202227 DOI: 10.1016/j.radonc.2017.01.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
3 Allard J, Le Guillou D, Begriche K, Fromenty B. Drug-induced liver injury in obesity and nonalcoholic fatty liver disease. Adv Pharmacol 2019;85:75-107. [PMID: 31307592 DOI: 10.1016/bs.apha.2019.01.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 7.3] [Reference Citation Analysis]
4 Alessandrino F, Tirumani SH, Krajewski KM, Shinagare AB, Jagannathan JP, Ramaiya NH, Di Salvo DN. Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors.Clin Radiol. 2017;72:521-533. [PMID: 28476244 DOI: 10.1016/j.crad.2017.04.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
5 Mingard C, Paech F, Bouitbir J, Krähenbühl S. Mechanisms of toxicity associated with six tyrosine kinase inhibitors in human hepatocyte cell lines. J Appl Toxicol 2018;38:418-31. [PMID: 29072336 DOI: 10.1002/jat.3551] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]